The Endo-HRS Model: A Novel Endoscopic Score for Predicting Recurrence in Internal Hemorrhoids – A Prospective Multicenter Cohort

RUNNING TITLE

Endo-HRS model for hemorrhoid recurrence

Feiyu Zhang, M.D.[1*] · Leiming Xu, M.D.[1*] · Fengyu Gao, M.D.[2] · Wen Wang, M.D.[3] · Wulian Lin, M.D.[3] · Hao Zhang, M.D.[4] · Kezhou Wang, M.D.[5] · Qingjing Wang, M.M[1,6] · Aojia Jin, Ph.D. candidate[1] · Ruping Yang, M.D. candidate [1] · Chunying Qu, M.D[1] · Yi Zhang, M.D.[1] · Zhenghong Li, M.D.[1] · Dou Wang, M.D.[7] · Cuicui Shi, M.D.[1] · Tianben Shen, B.N.[1] · Fei Shen, B.N.[1] · Ye Hu, M.D.[1†] · Feng Shen, M.D.[1,7†]

[1]Department of Gastroenterology & Endoscopy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

[2]Department of Endoscopy, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong Province, China

[3]Department of Gastroenterology, The 900th Hospital of the People's Liberation Army Joint Service Support Force, Fuzhou, Fujian Province, China

[4] Department of Endoscopy, Baoshan People's Hospital of Yunnan Province, Baoshan, Yunnan Province, China

[5]Department of Pathology, Xinhua Hospital Affiliated to Shanghai Jiao Tong

University School of Medicine, Shanghai, China

[6]Department of Gastroenterology, Jinshan Hospital of Fudan University, Shanghai, China

[7]Department of Gastroenterology, Shigatse People's Hospital, Shigatse, Tibet, China.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML and PDF versions of this article on the journal's website (www.dcrjournal.com).

Funding/Support: This work was supported by the Discipline Peak Climbing Plan of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Grant No. XKPF2024B404), the Shanghai Science and Technology Commission Innovation Ecosystem Construction Plan "Domestic Science and Technology Cooperation" Project (Grant No. 25010702300) and the National Natural Science Foundation of China (Grant No. 82472899)

Financial Disclosure: None reported.

Feiyu Zhang and Leiming Xu contributed equally to this article

Correspondence: Ye Hu, M.D., Department of Gastroenterology & Endoscopy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No.

1665 Kongjiang Rd, Shanghai, China. E-mail: huye@xinhuamed.com.cn; Feng Shen, M.D., Department of Gastroenterology & Endoscopy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Rd, Shanghai, China. E-mail: shenfeng01@xinhuamed.com.cn

Article type: Anorectal disease

ABSTRACT

BACKGROUND: The primary drawback of endoscopic foam sclerotherapy for grade I internal hemorrhoids is the high rate of recurrence. However, the pathological mechanisms underlying recurrence and reliable endoscopic predictive markers remain poorly defined.

OBJECTIVE: The study aimed to identify predictive factors and develop a novel endoscopic model to stratify recurrence risk following foam sclerotherapy for grade I internal hemorrhoids.

DESIGN: Multicenter, prospective, observational cohort study.

SETTINGS: This study was conducted at four tertiary hospitals.

PATIENTS: 483 patients with grade I internal hemorrhoids were enrolled and received foam sclerotherapy. 279 patients were independently enrolled for external validation.

INTERVENTIONS: Foam sclerotherapy was administered for patients.

MAIN OUTCOME MEASURES: The end point was recurrence of internal hemorrhoids.

RESULTS: Cumulative recurrence rates were 0.62%, 2.48%, 10.1%, and 20.0% at 6, 12, 24, and 36 months, respectively. The number of hemorrhoids, maximum hemorrhoid diameter, red color sign, and patient sex were identified as independent predictors and comprised the Endoscopic Hemorrhoid Recurrence Score (Endo-HRS) model. The model demonstrated strong discriminative ability (C-index=0.82; AUC>0.80) and stratified patients into three distinct risk categories (score <18.2,

18.2-27.4, ≥27.4) for personalized follow-up. A web-based calculator was developed for clinical implementation. Pathological analysis of recurrent lesions revealed submucosal microvascular congestion and aberrant deposition of extracellular matrix components.

LIMITATIONS: Limitations include lack of recalibration, generalizability, larger external and in vivo validation, and unity among observers.

CONCLUSIONS: The Endo-HRS model effectively stratifies recurrence risk following foam sclerotherapy for grade I internal hemorrhoids. The findings underscore the pathological contribution of abnormal extracellular matrix remodeling and excessive collagen deposition to recurrence. This tool addresses a significant gap in endoscopic hemorrhoid management by enabling individualized preoperative risk assessment and informing tailored treatment strategies.

CLINICAL TRIAL REGISTRATION NUMBER: NCT04398823.

See **Video Abstract.**

KEY WORDS

Internal hemorrhoids recurrence, Sclerotherapy, Predictive model, Endoscopy, Histopathology

INTRODUCTION

Internal hemorrhoids, characterized by symptomatic enlargement or distal displacement of the anal vascular cushions, represent one of the most prevalent anorectal disorders, affecting up to 40% of adults, particularly those over 40 years of age. Clinical manifestations primarily include bleeding, prolapse, and discomfort[1-2]. A wide spectrum of therapeutic options exists, ranging from conservative management to definitive surgical interventions[3-4]. Among these, endoscopic foam sclerotherapy with polidocanol has gained attention as a minimally invasive approach with rapid recovery and fewer postoperative adverse events[5-7]. Nevertheless, recurrence remains a major limitation, with rates of 10-30% reported within the first year[8-9], attributable to heterogeneous evaluation criteria and subjective clinical assessment. Existing classification systems, including the widely adopted Goligher classification, possess inherent limitations and have not facilitated a systematic analysis of predictive factors for recurrence.

This multicenter, prospective, observational cohort study aimed to identify predictive factors and develop a novel endoscopic model to stratify recurrence risk following foam sclerotherapy for grade I internal hemorrhoids, thereby informing optimized treatment strategies.

MATERIALS AND METHODS

Study design and population

A prospective, observational, multicenter cohort study was conducted to develop

and validate an endoscopic prediction model for recurrence after foam sclerotherapy for grade I hemorrhoids, adhering to the TRIPOD guideline[10]. Consecutive patients were enrolled between January 2018 and December 2022 at four tertiary Gastroenterology and Endoscopy centers in China, including Shanghai Xinhua Hospital, Shandong Provincial Maternal and Child Health Care Hospital, the 900th Hospital of the PLA Joint Service Support Force, and Baoshan People's Hospital.

The sample size was determined based on the expected number of recurrence events to ensure sufficient statistical power for multivariable modeling. Assuming a 3-year recurrence rate of 20-30%, a target enrollment exceeding 400 patients was set.

Eligible participants were adults (18-60 yrs) with endoscopically confirmed Goligher grade I hemorrhoids treated with 1% (20 mg / 2 mL) polidocanol (Aethoxysklerol, Hameln Pharmaceuticals, Germany) foam. Key exclusion criteria included advanced hemorrhoids, concomitant anorectal disorders, and contraindications to sclerotherapy. The detailed inclusion and exclusion criteria are presented in *Supplementary Table S1* & *S2*.

All participants provided written informed consent in accordance with the Declaration of Helsinki[11]. The study protocol was approved by the Ethics Committee of Xinhua Hospital (XHEC-C-2020-003-1) and is registered at ClinicalTrials.gov (NCT04398823).

Endoscopic therapy and data collection

Patients followed a low-fiber diet the day before colonoscopy and underwent split-dose bowel preparation using polyethylene glycol solution (Hengkangzhengqing,

Hygecon, Shangrao, Jiangxi, China), according to ESGE guidelines[12]. Foam sclerotherapy was administered using a standardized technique[13]. Specifically, 1% polidocanol was prepared by Tessari's method[14] and injected through a 25-gauge Interject™ needle (Boston Scientific, Marlborough, MA, United States) under endoscopic visualization (H290 series, Olympus, Tokyo, Japan).

Two experienced endoscopists, who underwent training based on a standardized protocol, independently recorded and evaluated the predefined endoscopic variables. These included the number of hemorrhoids, maximum hemorrhoid diameter, grade of red color sign, presence of mucosal erosion, and degree of dentate line injury. The evaluations were performed blinded to the operators who performed the procedures. Any discrepancies between the two assessors were resolved through consensus.

The number of hemorrhoids was confirmed using both anterograde and retroverted endoscopic views. Hemorrhoid diameter was measured with an endoscopic scale marker. The red color sign was graded on a scale of 0–3 according to the severity of vascular congestion: 0 (absent), 1 (scattered red dots on the hemorrhoid surface), 2 (linear red streaks on the surface), and 3 (large area of red congestion) (*Supplementary Figure S1*). Mucosal erosion was scored as present (1) or absent (0). Dentate line injury was classified as 0 (none), 1 (injury < 0.5 cm), or 2 (injury ≥ 0.5 cm) based on endoscopic observation.

Follow-up and outcomes

All patients underwent a minimum follow-up of 6 months, with scheduled clinic visits at 3-month intervals. Each visit included a clinical interview, digital rectal

examination, and standardized questionnaire assessments (*Supplementary Table S3*). All patients underwent protocolized surveillance colonoscopy every 6 months irrespective of symptoms. Besides, endoscopic confirmation was mandatory for any suspected recurrence, and all re-examination records were documented prospectively. Follow-up was extended up to 36 months in patients without recurrence and terminated immediately upon confirmed relapse. Recurrence was defined as the endoscopically confirmed reappearance of internal hemorrhoids associated with bleeding or definitive mucosal vascular abnormalities, whether detected during scheduled surveillance or prompted by symptoms. Time to recurrence was recorded in months.

Model development

Candidate predictors were first screened through univariable Cox proportional hazards regression. Variables with P < 0.10 were retained for multivariable analysis. The final model was derived by backward stepwise selection, with clinical relevance also considered in variable retention. The proportional hazards assumption was verified using Schoenfeld residuals. Hazard ratios (HRs) with 95% confidence intervals (CIs) are reported.

The ***Endo***scopic ***H***emorrhoid ***R***ecurrence ***S***core **(Endo-HRS)** was constructed by assigning weighted points to each independent predictor according to its regression coefficient. Model discrimination was assessed using Harrell's concordance index (C-index) and time-dependent receiver operating characteristic (tROC) curves. Calibration was evaluated with calibration plots. Internal validation was performed

using 1,000 bootstrap resamples to estimate optimism and adjust model performance.

Patients were then stratified into Endo-HRS groups A, B, and C according to the Youden-optimized cutoff. Recurrence-free interval among groups was compared using Kaplan-Meier analysis.

Web-based Endo-HRS calculator

An Endo-HRS web calculator was implemented. Model predictors are entered to automatically generate the weighted Endo-HRS score and classify patients into Endo-HRS group A (low risk), B (moderate risk), and C (high risk) based on predefined cutoffs. The online calculator is available at:

https://feiyuzhang.shinyapps.io/EndoHRS-Calculator/

External cohort validation of the Endo-HRS model

External validation was conducted in an independent cohort enrolled from separate clinical centers between January and December 2022, applying the same definitions and analytical strategy. No data from this cohort were used in model development.

Predictor definitions were harmonized with those of the development set. The original Cox proportional hazards model was applied to the external cohort without refitting, and individual linear predictors and risks were calculated using the regression coefficients derived from the development cohort.

Discrimination was evaluated with the C-index (95% CI obtained via 1,000 bootstrap resamples) and time-dependent ROC analysis at 24, 36, and 48 months. Calibration was assessed by comparing predicted and observed 36-month recurrence

probabilities using grouped calibration plots and a logit-LOESS smoothing approach. For clinical validation, patients were stratified as described above.

Multi-modal verification of the Endo-HRS model

A separate multi-modal verification cohort — comprising endoscopic and histopathological images — was obtained from participants not included in the development or external cohorts. During treatment, both antegrade and retroflexed endoscopic views were acquired. Two blinded endoscopists independently assessed endoscopic images for recurrence; disagreements were resolved by a third reviewer. Hemorrhoid tissue biopsies were obtained using standard forceps. Samples were processed for hematoxylin-eosin (H&E) and Masson's trichrome staining to evaluate vascular congestion and collagen deposition. Microvascular density and collagen proportionate area were quantified using ImageJ software[15].

Statistical analysis

Continuous variables are presented as mean ± standard deviation (SD) or median (interquartile range, IQR), and categorical variables as frequencies (%). Group comparisons were performed using the χ^2 test or Wilcoxon rank-sum test, as appropriate. Model discrimination and calibration were evaluated as described above.

Missing data were < 5% for all predictors; twenty imputations were generated using chained equations under a missing-at-random assumption. Median follow-up was estimated by the reverse Kaplan-Meier method. The distribution of censoring times (patients without recurrence) was visualized with a histogram to assess follow-up maturity.

All analyses were conducted in R (version 4.5.1; R Foundation for Statistical Computing, Vienna, Austria) and SPSS (version 27.0; IBM Corp., Armonk, NY, USA). Relevant R packages are listed in *Supplementary Table S4*. Custom R scripts for data processing and figure generation are available from the corresponding author upon reasonable request.

Statistical significance was set at $P < 0.05$. The study followed the TRIPOD reporting guideline for prognostic model development.

RESULTS

Patient characteristics and follow-up

A total of 504 patients with grade I hemorrhoids were prospectively enrolled across four centers. Twelve patients were excluded due to age >60 years, use of anticoagulant/antiplatelet therapy, or intolerance to endoscopic treatment. Nine patients were lost to follow-up. Consequently, 483 patients completed the study protocol and were included in the final analysis (*Figure 1A*).

The cohort comprised 50.9% (246/483) males, with a median age of 52.5 years (IQR 44–62). Recurrence occurred in 23.8% (115/483) of patients. The median age did not differ significantly between the recurrence and non-recurrence groups (55.0 ± 21.0 vs. 55.0 ± 18.0 years, P=0.82). However, the proportion of males was significantly higher in the recurrence group (61.7% [71/115]) compared to the non-recurrence group (47.6% [175/368], P=0.008). As expected, the observed follow-up duration was shorter in patients with recurrence (27.4 ± 9.3 vs. 61.0 ± 11.0

months, P=0.000006) because follow-up was terminated at the time of relapse (*Table 1*).

The median potential follow-up for the entire cohort, calculated using the reverse Kaplan-Meier method, was 61.0 months (95% CI 58.9-63.1), indicating comparable follow-up duration between groups. Among the 483 patients, 386 were censored. Censoring occurred predominantly after long-term follow-up, confirming sufficient observation time for recurrence assessment (*Supplementary Figure S2*).

The cumulative recurrence rates were 0.6% (3/483), 2.5% (12/483), 10.1% (49/483), and 20.0% (97/483) at 6, 12, 24, and 36 months, respectively, suggesting sustained efficacy of foam sclerotherapy over long-term follow-up.

Endoscopic characteristics

At baseline, the recurrence group had a significantly greater number of hemorrhoids (P=1.0E-101). Notably, 86.1% (99/115) of patients with recurrence presented with three or more hemorrhoids, compared to 52.7% (194/368) in the non-recurrence group. The recurrence group also exhibited a larger maximum hemorrhoid diameter (P=5.0E-15) and a higher frequency of moderate-to-severe red color signs (grade 2-3: 38.3% vs. 17.1%, P=4.0E-15). In contrast, no significant intergroup differences were observed for mucosal erosion (P=0.25) or dentate line injury (P=0.26) (*Table 2*).

Endo-HRS model construction

Based on these characteristics, a new prediction model was developed. The number of hemorrhoids, maximum diameter, and red color sign grade were identified

as strong independent predictors (all P<0.0001). Although male sex did not reach conventional statistical significance in the final model (P=0.08), it was retained due to its clinical relevance and consistency with prior literature. All four variables satisfied the proportional hazards assumption (*Figure 2*).

The final model demonstrated excellent discrimination without evidence of multicollinearity (*Supplementary Table S5*). Time-dependent ROC analysis confirmed its stability over time (*Supplementary Figure S3*). Calibration at 36 months showed a calibration-in-the-large of -2.51 and a calibration slope of 1.34, indicating a mild systematic underestimation of absolute risk. Nevertheless, predicted probabilities showed reasonable agreement with observed recurrences across risk deciles in the internal validation (*Supplementary Figure S4*).

$$Risk\ Score = 1\times Sex(male) + 4\times Num + 11\times Dia + 2\times RCS \quad (1)$$

*Regression coefficients were scaled by dividing each β by the smallest coefficient (sex), multiplying by 2, and rounding to the nearest integer to generate a clinically usable score. Abbreviations: Sex: male=1, female=0; Num: number of hemorrhoids; Dia: maximum hemorrhoid diameter (cm); RCS: red color sign grade (0-3). *

Based on the model, patients were initially stratified into quartile-based risk groups (low, moderate, high, very high; *Supplementary Table S6*). For clinical utility, a simplified three-tier system (Endo-HRS groups A, B, C) was derived (*Supplementary Table S7*), which showed good discrimination at 36 months (AUC=0.86, Youden-optimized cutoff=22.8; *Figure 3A*). Recurrence-free interval

probability decreased progressively across these risk groups (*Figure 3B*). Individual recurrence risk could also be estimated using a nomogram (*Figure 3C*).

A web-based Endo-HRS calculator was implemented to enable real-time risk estimation using the four predictors included in the Endo-HRS model. The tool automatically outputs both the total score and corresponding risk category for individual patients. The interface of the calculator is shown in *Supplementary Figure S5*.

External and multi-modal verification

External validation was performed in an independent cohort of 279 patients (*Figure 1B*). The Endo-HRS model demonstrated strong discrimination in this cohort (bootstrap-corrected C-index=0.900, 95% CI 0.862-0.933), with time-dependent AUCs exceeding 0.90 at 24, 36, and 48 months (*Figure 4A*). Calibration curves indicated good agreement between predicted and observed recurrence (*Supplementary Figure S6*). Patients in group C had a significantly shorter recurrence-free interval compared to those in groups A and B (P=0.000008; *Figure 4B*).

For multi-modal verification, a subset of 40 participants was included. According to the Endo-HRS model, 9 patients were classified as group A, 24 as group B, and 7 as group C (*Supplementary Table S8*).

Endoscopic imaging analysis confirmed that higher-risk groups exhibited more prominent red color signs, a greater number of hemorrhoids, and larger diameters (*Figure 5A-C*), indicating that the Endo-HRS classification corresponded well with endoscopic severity and clinical outcomes (P=8.0E-8).

Histopathological analysis further validated the model. Patients in the Endo-HRS C group showed marked dilation and congestion of submucosal venules (*Figure 5D–F*), consistent with a higher clinical bleeding tendency. Masson's trichrome staining revealed significantly denser collagen deposition in higher-risk groups (*Figure 5G–I*). The collagen proportionate area was 14.6-fold and 2.6-fold higher in group C compared to groups A and B, respectively (*Supplementary Table S9, Figure S7*). These findings demonstrate consistency between the pathological substrate and the clinical model, suggesting that recurrence risk may be driven by both vascular abnormalities and aberrant collagen deposition.

DISCUSSION

To our knowledge, this is the first prospective study to evaluate the 3-year recurrence rate following 1% polidocanol foam sclerotherapy for grade I internal hemorrhoids. Prior research has not specifically addressed long-term outcomes in this patient subgroup. We developed the Endo-HRS, the first prediction model derived from objective endoscopic features. Unlike previous symptom-based classifications, the Endo-HRS incorporates quantifiable endoscopic parameters and has undergone rigorous multi-modal validation involving an independent clinical cohort, endoscopic imaging, and histopathological analysis. This approach not only confirms the robustness of the model but also establishes a novel framework linking clinical presentation with underlying pathological mechanisms. To facilitate clinical implementation, we have developed a companion web-based application for

point-of-care risk stratification.

Recurrence increased progressively over time, with rates of 2.5%, 10.1%, and 20.0% at 1, 2, and 3 years, respectively. These findings are consistent with prior reports[6, 16], although prior studies predominantly employed 3% (60mg/2mL) polidocanol and included patients with grade II-III hemorrhoids[6, 16-18]. Our results suggest that 1% polidocanol foam maintains therapeutic efficacy for grade I disease while potentially reducing local tissue irritation, resulting in comparatively lower recurrence rates[13]. Notably, no severe adverse events (e.g., thrombosed hemorrhoids or perianal abscesses) were observed, underscoring the safety profile of this regimen. The 3-year recurrence rate of 20% in our grade I cohort appears favorable compared to the 12-28% recurrence reported for 3% polidocanol in grade II hemorrhoid[19].

Despite the substantial clinical burden of hemorrhoidal disease[20], dedicated research on internal hemorrhoids remains limited. Traditional grading systems such as Goligher's classification emphasize prolapse but inadequately capture bleeding and other symptomatic dimensions[21]. Even more recent classifications, including the BPRST system[22], remain largely symptom-based. Previous investigations have focused on subjective factors like constipation, pruritus, and lifestyle habits[23-25]. In contrast, our model incorporated objective endoscopic indicators — hemorrhoid number (HR of 3.39), maximum diameter (HR of 22.94), and red color sign grade (HR of 1.67) — which emerged as strong independent predictors of recurrence. Although male sex did not retain statistical significance in the final model (P=0.08), it was included due to its clinical relevance (61.7% recurrence vs 47.6% no-recurrence)

and consistency with existing literature[23], without compromising model validity.

During model development, patients were stratified into four risk categories based on score quartiles, with Kaplan-Meier analysis confirming significant differences in recurrence-free interval across these strata (*Supplementary Figure S8*). However, a four-tier system may prove cumbersome in routine practice, where repeated endoscopic reassessment is often impractical and could reduce patient compliance. To enhance clinical utility, we simplified the stratification into three distinct Endo-HRS groups (A, B, C). This pragmatic system supports resource-appropriate management: patients with scores <18.2 may defer intensive endoscopic surveillance for 2-3 years, while those with scores ≥27.4 should undergo regular monitoring and be considered for earlier re-intervention. The accompanying web application allows clinicians to obtain instant risk stratification by inputting key parameters, thereby streamlining clinical workflow.

To strengthen the robustness and biological interpretability of the Endo-HRS, we employed a multi-modal verification strategy. The integration of endoscopic imaging with histopathological analysis not only validated the clinical risk stratification but also provided mechanistic insights. While symptomatic management has dominated hemorrhoid research, its underlying biology remains poorly understood. Recent genomic studies have shed new light: Zheng et al.[26] demonstrated heritability and implicated vascular pathways and extracellular matrix (ECM) remodeling in hemorrhoid etiology, and Sninsky et al.[27] suggested shared genetic determinants with diverticulosis mediated through connective tissue alterations. Our findings directly

complement this evidence. Endoscopically, higher-risk patients exhibited larger hemorrhoids and more prominent red color signs, suggesting vascular hyperplasia. Histologically, these features corresponded to marked venous dilation and congestion on H&E staining, alongside significantly increased collagen deposition on Masson's trichrome staining — both correlating with recurrence risk. Given that collagen is a key structural component of the ECM[28] and that ECM integrity is fundamental to vascular homeostasis[29], these results support a pathophysiological mechanism whereby abnormal ECM remodeling and excessive collagen production may drive recurrence. Together, these convergent multi-modal observations provide supportive, albeit exploratory, pathophysiological evidence linking clinical features to underlying biological mechanisms, thereby reinforcing the validity and translational potential of the Endo-HRS model.

This study has several limitations. Although the Endo-HRS demonstrated excellent discrimination, calibration at 36 months revealed a tendency toward systematic underestimation of absolute risk, suggesting that probability estimates may require recalibration before broad external application. First, the model was developed exclusively in Chinese patients with Goligher grade I hemorrhoids treated with foam sclerotherapy, which may limit generalizability to other populations, hemorrhoid grades, or treatment modalities. Second, further external validation in larger, more diverse cohorts is warranted. Third, while endoscopic features are more objective than symptoms, inter-observer variability remains a consideration; standardized training protocols and future artificial-intelligence-assisted assessments could improve

reproducibility. Finally, the mechanistic insights derived from histology, though compelling, require further in vivo validation.

In conclusion, this study establishes an endoscopy-based model for predicting recurrence after foam sclerotherapy for internal hemorrhoids. The Endo-HRS provides a practical, validated tool for risk stratification, enabling individualized follow-up and treatment planning, and represents a step toward personalized management of hemorrhoidal disease.

ACKNWLEDGEMENTS

The authors are grateful to all patients for their consent to participate and for sharing their treatment and follow-up data. All authors take full responsibility for the content of this work.

REFERENCE

1. Tomasicchio G, Martines G, Lantone G, et al. Safety and Effectiveness of Tailored Hemorrhoidectomy in Outpatients Setting. *Front Surg*. 2021;8:708051. doi:10.3389/fsurg.2021.708051

2. Lee KC, Liu CC, Hu WH, Lu CC, Lin SE, Chen HH. Risk of delayed bleeding after hemorrhoidectomy. *Int J Colorectal Dis*. 2019;34(2):247-253. doi:10.1007/s00384-018-3176-6

3. Sikakulya FK, Ssebuufu R, Okedi XF, et al. Pain assessment following open hemorrhoidectomy under local anesthesia versus saddle block: a multicenter

randomized controlled trial. *BMC Surg*. 2023;23(1):124. doi:10.1186/s12893-023-02030-6

4. Lauricella S, Palmisano D, Brucchi F, et al. Long-term results and quality of life after stapled hemorrhoidopexy vs Doppler-guided HAL-RAR: a propensity score matching analysis. *Int J Colorectal Dis*. 2024;39(1):30. doi:10.1007/s00384-024-04603-0

5. Zhang FM, Wu KC, Li JN, et al. Rationale, new anus positioning methods, and updated protocols: Expert recommendations on cap-assisted endoscopic sclerotherapy for hemorrhoids from China Gut Conference. *Chin Med J (Engl)*. 2021;134(22):2675-2677. doi:10.1097/cm9.0000000000001836

6. Salgueiro P, Garrido M, Santos RG, Pedroto I, Castro-Poças FM. Polidocanol Foam Sclerotherapy Versus Rubber Band Ligation in Hemorrhoidal Disease Grades I/II/III: Randomized Trial. *Dis Colon Rectum*. 2022;65(7):e718-e727. doi:10.1097/dcr.0000000000002117

7. Gallo G, Grossi U, De Simone V, et al. Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations. *Updates Surg*. 2025;77(5):1439-1450. doi:10.1007/s13304-025-02258-2

8. Wu X, Wen Q, Cui B, et al. Cap-assisted endoscopic sclerotherapy for internal hemorrhoids: technique protocol and study design for a multi-center randomized controlled trial. *Ther Adv Gastrointest Endosc*. 2020;13:2631774520925636. doi:10.1177/2631774520925636

9. Takada S, Tsunoda A, Takahashi T, Kusanagi H. Early postoperative outcomes of a novel nonexcisional technique using aluminum potassium sulfate and tannic acid sclerotherapy with mucopexy on patients with grade III hemorrhoids. *Ann Coloproctol*. 2022;38(4):290-296. doi:10.3393/ac.2020.00920.0131

10. Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. *Bmj*. 2024;385:e078378. doi:10.1136/bmj-2023-078378

11. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. *JAMA*. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053

12. Hassan C, East J, Radaelli F, et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. *Endoscopy*. 2019;51(8):775-794. doi:10.1055/a-0959-0505

13. Qu CY, Zhang FY, Wang W, et al. Endoscopic polidocanol foam sclerobanding for the treatment of grade II-III internal hemorrhoids: A prospective, multi-center, randomized study. *World J Gastroenterol*. 2024;30(27):3326-3335. doi:10.3748/wjg.v30.i27.3326

14. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. *Dermatol Surg*. 2001;27(1):58-60.

15. Schroeder AB, Dobson ETA, Rueden CT, Tomancak P, Jug F, Eliceiri KW. The ImageJ ecosystem: Open-source software for image visualization, processing, and analysis. *Protein Sci*. 2021;30(1):234-249. doi:10.1002/pro.3993

16. Gallo G, Pietroletti R, Novelli E, et al. A multicentre, open-label, single-arm phase II trial of the efficacy and safety of sclerotherapy using 3% polidocanol foam to treat second-degree haemorrhoids (SCLEROFOAM). *Tech Coloproctol*. 2022;26(8):627-636. doi:10.1007/s10151-022-02609-w

17. Lobascio P, Laforgia R, Novelli E, et al. Short-Term Results of Sclerotherapy with 3% Polidocanol Foam for Symptomatic Second- and Third-Degree Hemorrhoidal Disease. *J Invest Surg*. 2021;34(10):1059-1065. doi:10.1080/08941939.2020.1745964

18. Neves S, Falcão D, Povo A, Castro-Poças F, Oliveira J, Salgueiro P. 3% polidocanol foam sclerotherapy versus hemorrhoidal artery ligation with recto anal repair in hemorrhoidal disease grades II-III: a randomized, pilot trial. *Rev Esp Enferm Dig*. 2023;115(3):115-120. doi:10.17235/reed.2022.8568/2022

19. Gallo G, Picciariello A, Pietroletti R, et al. Sclerotherapy with 3% polidocanol foam to treat second-degree haemorrhoidal disease: Three-year follow-up of a multicentre, single arm, IDEAL phase 2b trial. *Colorectal Dis*. 2023;25(3):386-395. doi:10.1111/codi.16380

20. Cosman BC. Piles of Money: “Hemorrhoids” Are a Billion-Dollar Industry. *Am J Gastroenterol*. 2019;114(5):716-717. doi:10.14309/ajg.0000000000000234

21. Dekker L, Han-Geurts IJM, Grossi U, Gallo G, Veldkamp R. Is the Goligher classification a valid tool in clinical practice and research for hemorrhoidal disease? *Tech Coloproctol*. 2022;26(5):387-392. doi:10.1007/s10151-022-02591-3

22. Margetis N. Pathophysiology of internal hemorrhoids. *Ann Gastroenterol*. 2019;32(3):264-272. doi:10.20524/aog.2019.0355

23. Sandler RS, Peery AF. Rethinking What We Know About Hemorrhoids. *Clin Gastroenterol Hepatol*. 2019;17(1):8-15. doi:10.1016/j.cgh.2018.03.020

24. Lohsiriwat V, Sheikh P, Bandolon R, et al. Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review. *Adv Ther*. 2023;40(1):117-132. doi:10.1007/s12325-022-02351-7

25. Rørvik HD, Styr K, Ilum L, et al. Hemorrhoidal Disease Symptom Score and Short Health ScaleHD: New Tools to Evaluate Symptoms and Health-Related Quality of Life in Hemorrhoidal Disease. *Dis Colon Rectum*. 2019;62(3):333-342. doi:10.1097/dcr.0000000000001234

26. Zheng T, Ellinghaus D, Juzenas S, et al. Genome-wide analysis of 944 133 individuals provides insights into the etiology of haemorrhoidal disease. *Gut*. 2021;70(8):1538-1549. doi:10.1136/gutjnl-2020-323868

27. Sninsky JA, Galanko J, Sandler RS, Peery AF. Diverticulosis Is Associated With Internal Hemorrhoids on Colonoscopy: Possible Clues to Etiology. *Clin Gastroenterol Hepatol*. 2023;21(4):1097-1099.e3. doi:10.1016/j.cgh.2022.02.020

28. De Martino D, Bravo-Cordero JJ. Collagens in Cancer: Structural Regulators and Guardians of Cancer Progression. *Cancer Res*. 2023;83(9):1386-1392. doi:10.1158/0008-5472.Can-22-2034

29. Fu Y, Zhou Y, Wang K, Li Z, Kong W. Extracellular Matrix Interactome in Modulating Vascular Homeostasis and Remodeling. *Circ Res*. 2024;134(7):931-949. doi:10.1161/circresaha.123.324055

TABLES

Table 1. Baseline clinical characteristics of patients in recurrence and no recurrence groups.

Participants (n=483)		Recurrence (n=115)	No recurrence (n=368)	P value
Age		55.0±21.0	55.0±18.0	0.82
Sex	**Male**	61.7% (n=71)	47.6% (n=175)	0.008**
	Female	38.3% (n=44)	52.4% (n=193)	
Follow-up period		27.4±9.3	61.0±11.0	0.000006***
Median follow-up, months (95% CI[a])		61.0 (58.9-63.1)		/

a. CI: confidence interval

Table 2. Endoscopic characteristics of patients in recurrence and no recurrence groups.

Participants	Number of hemorrhoids					Maximum hemorrho	
(n=483)	1	2	3	4	5	<0.8cm	0.8cm≤Dia.<1
Recurrence (n=115)	0.0% (n=0)	13.9% (n=16)	62.6% (n=72)	22.6% (n=26)	0.9% (n=1)	3.5% (n=4)	61.7% (n=7
No recurrence (n=368)	8.4% (n=31)	38.9% (n=143)	49.7% (n=183)	3.0% (n=11)	0.0% (n=0)	34.2% (n=126)	54.9% (n=20
P value	1.0E-101***					5.0E-15***	

(Continued)

Participants	Grade of red color sign				Mucosa erosion		Dentate li	
(n=483)	0	1	2	3	No	Yes	0	<0.5
Recurrence (n=115)	4.3% (n=5)	57.4% (n=66)	27.0% (n=31)	11.3% (n=13)	91.3% (n=105)	8.7% (n=10)	87.8% (n=101)	9.((n=
No recurrence (n=368)	41.6% (n=153)	41.3% (n=152)	17.1% (n=63)	0.0% (n=0)	94.3% (n=347)	5.7% (n=21)	91.3% (n=336)	7.1 (n=
P value	4.0E-15***				0.25			0.1

LEGENDS

Graphical Abstract: Patients with Goligher's grade I internal hemorrhoids receiving foam sclerotherapy were analyzed for endoscopic and clinical features. The Endoscopic Hemorrhoid Recurrence Score (Endo-HRS) was developed and externally validated with independent cohorts and endoscopic/histopathological correlation. Endo-HRS provides individualized recurrence risk stratification after endoscopic treatment to guide clinical management.

Figure 1. Study cohort flowchart. A. Development cohort. B. External validation cohort.

Figure 2. Forest plot of variables in the prediction model.

Figure 3. Model performance and clinical application of the Endo-HRS. A. Time-dependent receiver operating characteristic (ROC) curve for predicting 36-month recurrence. The bronze, green, and blue dots represent rule-in, Youden-optimized, and rule-out thresholds, respectively. B. Kaplan-Meier curves of recurrence-free interval stratified by Endo-HRS groups A (blue), B (green), and C (bronze). C. Nomogram for predicting the individual probability of recurrence at 36 months. Abbreviations: AUC, area under curve.

Figure 4. External validation of the Endo-HRS model. A. Time-dependent receiver operating characteristic (ROC) curves for recurrence prediction at 24 (bronze), 36 (green), and 48 (blue) months. B. Kaplan-Meier recurrence-free interval curves for Endo-HRS groups A (blue), B (green), and C (bronze).


A
Development cohort
Assessed for eligibility
(n=504)
Excluded (n=12)
- Over the age limit: n=3
- Taking oral anticoagulant or antiplatelet drugs: n=8
- Unable to tolerate endoscopic treatment: n=1
Included in prospective cohort
(n=492)
Follow-up
- Completed (n=483)
- Lost (n=9)
Included in final analysis
(n=483)
B
External validation cohort
Assessed for eligibility
(n=291)
Excluded (n=5)
- Over the age limit: n=3
- Taking oral anticoagulant or antiplatelet drugs: n=2
Included in prospective cohort
(n=286)
Follow-up
- Completed (n=279)
- Lost (n=7)
Included in final analysis
(n=279)


Variable
HR
(95% CI)
Sex (male)
1.32
(0.90−1.92)
Number of
hemorrhoids
3.39
(2.44−4.72)
Maximum hemorrhoid
diameter
22.94
(6.97−75.52)
Grade of
red color sign
1.67
(1.24−2.25)
1.0
2.0
4.0
8.0
16.0
32.0
64.0
Hazard Ratio (95% CI)


A
Time-dependent ROC curves at 36 months
Sensitivity
1-Specificity
Youden
Rule-out
Rule-in
0.0
0.2
0.4
0.6
0.8
1.0


B
Risk Group
Endo-HRS Group A
Endo-HRS Group B
Endo-HRS Group C
Recurrence-free Internal
Follow-up Time (months)
p < 0.0001
1.00
0.75
0.50
0.25
0.00
0
20
40
60
80


C
Points
0 10 20 30 40 50 60 70 80 90
Sex
male
female
Number of hemorrhoids
2 4
1 3 5
Maximum hemorrhoid diameter
0.6 0.9 1.2
0.5 0.8 1 1.3
Grade of red color sign
2 4
1 3
Total points
0 20 40 60 80 120 160
36-month Recurrence Probability
90 70 50 30 10


A
Sensitivity
1-Specificity
0.0
0.2
0.4
0.6
0.8
1.0
24 mo, AUC=0.90
36 mo, AUC=0.94
48 mo, AUC=0.95
B
Risk Group
Endo-HRS A
Endo-HRS B
Endo-HRS C
Recurrence-free Probability
1.00
0.75
0.50
0.25
0.00
p < 0.0001
0
20
40
60
Follow-up Time (months)


A
B
C
D
E
F
G
H
I


Internal hemorrhoids
Bleeding
Pain
Age
Sex
Baseline characteristics
Model construction
Endo-HRS Model
Endo-HRS C
C
B
Endo-HRS B
Endo-HRS A
A
Follow-up
External cohort
Endo-images
Patho-images
Multi-modal verification
Number
Diameter
Red color sign
Mucosa
Dentate line
Endoscopic characteristics
Liquid
Polidocanol
Foam
Endoscopic foam sclerotherapy